Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine: current landscape
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl adolygu › adolygiad gan gymheiriaid
StandardStandard
Yn: Nanomedicine, Cyfrol 13, 16.11.2018, t. 7575-7605.
Allbwn ymchwil: Cyfraniad at gyfnodolyn › Erthygl adolygu › adolygiad gan gymheiriaid
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Nanodelivery systems and stabilized solid-drug nanoparticles for orally administered medicine
T2 - current landscape
AU - Kermanizadeh, Ali
AU - Powell, Leagh G
AU - Stone, Vicki
AU - Møller, Peter
PY - 2018/11/16
Y1 - 2018/11/16
N2 - The use of nanoparticles as a means of targeted delivery of therapeutics and imaging agents could greatly enhance the transport of biologically active contents to specific target tissues, while avoiding or reducing potentially undesired side effects. Generally speaking, the oral route of administration is associated with good patient compliance, as it is convenient, economical, noninvasive, and does not require special training. Here, we review the progress of the utilization of nanodelivery-system carriers or stabilized solid-drug nanoparticles following oral administration, with particular attention on toxicological data. Mechanisms of cytotoxicity are discussed and the problem of extrapolating knowledge to human scenarios highlighted. Additionally, issues associated with administration of drugs via the oral route are underlined, while strategies utilized to overcome these are highlighted. This review aims to offer a balanced overview of strategies currently being used in the application of nanosize constructs for oral medical applications.
AB - The use of nanoparticles as a means of targeted delivery of therapeutics and imaging agents could greatly enhance the transport of biologically active contents to specific target tissues, while avoiding or reducing potentially undesired side effects. Generally speaking, the oral route of administration is associated with good patient compliance, as it is convenient, economical, noninvasive, and does not require special training. Here, we review the progress of the utilization of nanodelivery-system carriers or stabilized solid-drug nanoparticles following oral administration, with particular attention on toxicological data. Mechanisms of cytotoxicity are discussed and the problem of extrapolating knowledge to human scenarios highlighted. Additionally, issues associated with administration of drugs via the oral route are underlined, while strategies utilized to overcome these are highlighted. This review aims to offer a balanced overview of strategies currently being used in the application of nanosize constructs for oral medical applications.
KW - Administration, Oral
KW - Disease
KW - Drug Delivery Systems
KW - Humans
KW - Nanoparticles/chemistry
KW - Pharmaceutical Preparations/administration & dosage
U2 - 10.2147/IJN.S177418
DO - 10.2147/IJN.S177418
M3 - Review article
C2 - 30510419
VL - 13
SP - 7575
EP - 7605
JO - Nanomedicine
JF - Nanomedicine
ER -